Drug
Ustekinumab clinical trials
Also written Stelara and CNTO 1275.
- studies test it
- 102
- open now
- 11
- in phase 3
- 40
- first study started
- 2003
Keep track of what changes. Save the Ustekinumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Stelara
- 35
Combined with it in one product
Studies by the year they started
102 studies that test it; most in 2021 (14)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 3 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 6 |
| 2013 | 3 |
| 2014 | 5 |
| 2015 | 8 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 6 |
| 2019 | 4 |
| 2020 | 11 |
| 2021 | 14 |
| 2022 | 6 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 17
- Phase 2
- 35
- Phase 3
- 40
- Phase 4
- 15
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 57 · Other 45
Janssen Research & Development, LLC (28) · Centocor, Inc. (10) · Janssen Pharmaceutical K.K. (4) · Assistance Publique - Hôpitaux de Paris (3) · University of British Columbia (2) · Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW (2) · Janssen-Cilag Ltd. (2) · Amgen (2)
Often tested with
Tested in the same studies.
Guselkumab (8) · Adalimumab (7) · Secukinumab (7) · Methotrexate (4) · Etanercept (4) · Infliximab (4) · Dupilumab (3) · Golimumab (3)
Studies
Open first, then newest update. How each study uses Ustekinumab is read from its arms, and is right about nine times in ten.
Testing it · 102
- Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer PatientsRecruitingPhase 2M.D. Anderson Cancer CenterNCT06807593Written as Ustekinumab
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Ustekinumab
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Ustekinumab
- Development of Predictive Psoriasis Response Endotypes Using Single Cell TranscriptomicsRecruitingPhase 4University Hospitals Cleveland Medical CenterNCT05270733Written as Ustekinumab
- Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's DiseaseRecruitingPhase 4Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT06520397Written as Ustekinumab and Upadacitinib
- De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative ColitisRecruitingPhase 4McGill University Health Centre/Research Institute of the McGill University Health CentreNCT07303686Written as Ustekinumab 90 mg SC q8w
- Biologics in Folliculitis Decalvans : an Adaptative Trial ResearchNot yet recruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT07268534Written as Ustekinumab
- Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative ColitisRecruitingPhase 2Medical University of LodzNCT06453317Written as Ustekinumab
- Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis.RecruitingPhase 1University Medical Center GroningenNCT05725876Written as Ustekinumab
- Effects of Treatment With Biological Agents on Vascular and Cardiac Function in PsoriasisRecruitingPhase 4University of AthensNCT02144857Written as ustekinumab
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingPhase 3University of Erlangen-Nürnberg Medical SchoolNCT04610476Written as Ustekinumab
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's DiseaseActive, not recruitingPhase 4TakedaNCT06045754Written as Ustekinumab
- A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)CompletedPhase 3Janssen Research & Development, LLCNCT04630028Written as Ustekinumab Dose Based on BSA and Body Weight
- An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation StudyCompletedPhase 3Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZWNCT05299931Written as Ustekinumab
- A Long-term Extension Study of Ustekinumab in Pediatric ParticipantsActive, not recruitingPhase 3Janssen Research & Development, LLCNCT05092269Written as Ustekinumab
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseaseActive, not recruitingPhase 2/3Janssen Research & Development, LLCNCT03466411Written as Ustekinumab
- A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic ArthritisCompletedPhase 3Janssen Research & Development, LLCNCT05083182Written as Ustekinumab
- A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseCompletedPhase 3Janssen Research & Development, LLCNCT04673357Written as Ustekinumab
- Loss of RESponse to Ustekinumab Treated by Dose EscalationCompletedPhase 3Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZWNCT04245215Written as Ustekinumab
- Using a Contact Dermatitis Model With Biologic Medications to Study Skin InflammationActive, not recruitingPhase 2/3Wei-Che KoNCT05535738Written as Ustekinumab
See all 102 studies that test Ustekinumab →
Given in every arm · 9 — Ustekinumab is usual care beside what is tested
- Stelara and Diet Trial for Crohn"s DiseaseNot yet recruitingNot applicableWolfson Medical CenterNCT04779762Written as Ustekinumab Injection [Stelara]
- A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's DiseaseTerminatedPhase 2Boehringer IngelheimNCT04978493Written as Ustekinumab
- A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease SymptomsCompletedPhase 3AbbVieNCT04435600Written as Ustekinumab
- A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's DiseaseWithdrawnPhase 2Janssen Research & Development, LLCNCT04655807Written as Ustekinumab
- Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)CompletedPhase 2Janssen Research & Development, LLCNCT02319759Written as Ustekinumab
- Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsACompletedPhase 3Dr. Frank BehrensNCT03148860Written as Ustekinumab
- Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis VulgarisCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01999868Written as Ustekinumab
- Safety Study of BMS-986202 in Healthy Subjects and to Treat PsoriasisCompletedPhase 1Bristol-Myers SquibbNCT02763969Written as Ustekinumab
- A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to MethotrexateCompletedPhase 4Janssen-Cilag International NVNCT01059773Written as Ustekinumab
As the comparator · 27 — what is tested is compared with Ustekinumab
- An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With UstekinumabRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03167437Written as Ustekinumab
- Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)RecruitingPhase 3Bristol-Myers SquibbNCT07116967Written as Ustekinumab
- Risankizumab for Fibrostenotic Crohn's Disease TreatmentNot yet recruitingPhase 3First Affiliated Hospital of Wenzhou Medical UniversityNCT07177118Written as Ustekinumab
- Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled StudyNot yet recruitingPhase 3Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT07149467Written as Ustekinumab (approximately 6 mg/kg)
- A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque PsoriasisActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06934226Written as Ustekinumab
- An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3AO GENERIUMNCT06488664Written as Stelara®
- A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque PsoriasisActive, not recruitingPhase 3UCB Biopharma SRLNCT06425549Written as ustekinumab
- A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 3UCB Biopharma SRLNCT03370133Written as Ustekinumab
- Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)Active, not recruitingPhase 3AbbVieNCT04524611Written as Ustekinumab
- Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 3Biocon Biologics UK LtdNCT05335356Written as Stelara
- A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque PsoriasisCompletedPhase 3Samsung Bioepis Co., Ltd.NCT04967508Written as Stelara® (Ustekinumab)
- A Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseaseCompletedPhase 3Eli Lilly and CompanyNCT03926130Written as Ustekinumab
- A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy VolunteersCompletedPhase 1AO GENERIUMNCT06481215Written as Stelara®
- Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 3Dong-A ST Co., Ltd.NCT04785326Written as Stelara
- Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ CapsuleCompletedPhase 1RANI TherapeuticsNCT05890118Written as Stelara
- Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3Bio-Thera SolutionsNCT04728360Written as Stelara (EU-sourced)
- A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque PsoriasisCompletedPhase 3CelltrionNCT04673786Written as Stelara
- Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque PsoriasisCompletedPhase 3Alvotech Swiss AGNCT04930042Written as Stelara
- Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy AdultsCompletedPhase 1BioFactura Australia Pty Ltd.NCT04843631Written as EU-STELARA®
- Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy SubjectsCompletedPhase 1Bio-Thera SolutionsNCT04371185Written as Stelara(US-licensed)
Showing 20 of 27.
Codes
What other systems call Ustekinumab · ClinicalTrials.gg INT006608
- MeSH (NLM) D000069549UstekinumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) FU77B4U5Z0USTEKINUMABConfirmed FDA, NLM, Wikidata
- RxNorm 847083Confirmed FDA, Wikidata
- Wikidata Q420305ustekinumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C84237UstekinumabOne source FDA
- DrugBank DB05679One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069549 | Ustekinumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | FU77B4U5Z0 | USTEKINUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 847083 | — | Confirmed FDA, Wikidata |
| Wikidata | Q420305 | ustekinumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C84237 | Ustekinumab | One source FDA |
| DrugBank | DB05679 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.